Introduction and hypothesis We used a focus-group methodology to gather information about women's knowledge and attitudes regarding research participation. Methods Two in-person focus groups at seven clinical sites were conducted in women with pelvic floor disorder (PFD): one of women with clinical trial study experience and the other without such experience. One Web-based focus group combining both groups was also conducted. Results One hundred and five women (average age 58.6 years) participated. Participants in both groups believed that their physicians were the best source of information about clinical trials yet felt that other sources of trial information were important. Financial compensation was not a primary motivating factor for PFD trial enrollment but was, however, cited as an important consideration. Internet collection of data was feasible and provided information comparable with in-person focus groups. Conclusions This study identified central themes guiding successful recruitment to and retention in PFD-related trials and provided insight regarding strategies that may guide future trials.
Introduction
Pelvic floor disorders (PFD) have a significant impact on women's quality of life (QoL) and on the health care system because of the large number of affected women and the costs associated with diagnosing and managing these disorders. Luber et al. estimated that over the 30 years, the demand for services for PFD will increase at twice the population growth rate, outstripping resources for care [1] . An increase in patient-centered comparative effectiveness research and well-done prospective cohort studies has improved our understanding of the pathophysiology of these disorders and improved treatment outcomes. However, given the burden of PFDs on women and the health care system, continued research is needed to further optimize treatment outcomes.
Little is known about the factors influencing patients' decisions to initiate and continue participation in PFD research studies. Qualitative research regarding recruitment and retention of women in PFD studies is lacking. Specifically, we are aware of no published studies on this topic that employed focus-group methodology (i.e., where a small group of participants selected from a wider population of interest participate in a group discussion led by experienced moderators to ascertain the individuals' opinions or responses to particular subject areas). Furthermore, special population groups in clinical research, such as ethnic and racial minorities, may pose additional recruitment and retention challenges [2] . As a part of the US National Cancer Institute (NCI)-funded Community Retention Intervention Study [3] , researchers found that the use of focusgroup information can be effectively applied to understand retention and compliance strategies in clinical trials of underserved women.
Efficient use of research resources is imperative given the economic limitations of research-funding opportunities. Increasingly, potential and active patients use Web-based methods (e.g., accessing the Internet) for acquiring information regarding clinical care and research opportunities. Literature specific to the conduct of Web-based focus groups (where participants join the group discussion via a personal computer accessing the Internet instead of in-person participation) of women with PFD does not exist. However, Webbased methods have been assessed in other populations, providing preliminary evidence that comparable levels of data quantity and quality [4] can be achieved, with the additional ability to reach remote, small, and hard-to-include populations [5] [6] [7] . Additionally, Web-based focus groups provide participants with a comfortable and convenient way of joining group discussions [8] .
The aim of this multisite study was to employ focusgroup methodology to gather data to inform PFD researchers about the knowledge and attitudes of women regarding research participation. We hope to use this data to develop new incentive strategies aimed at increasing recruitment and retention of research participants in long-term clinical trials. We also explored Web-based focus groups, as this approach is becoming an increasingly popular method for collecting qualitative data.
Methods
We conducted two in-person focus groups near each of the seven clinical sites of the Pelvic Floor Disorders Network (PFDN). At each site, one focus group was conducted with women with previous or current PFD randomized clinical trial (RCT) participation (study-experienced); the other was conducted with women without PFD study participation (study-naïve). In addition to these 14 focus groups, we conducted two Web-based focus groups, one each for study-experienced and study-naïve women. The goal of this sampling method was to include each PFDN site and reach saturation on the topic area.
Following Institutional Review Board (IRB) approval by all research entities, study coordinators at each site identified women who met eligibility criteria. Adult women >21 years, living independently, with English fluency, and who had a current or prior PFD diagnosis, were approached to participate. Targeted recruitment of minority women was individualized per site to be consistent with the clinical sites' historical minority recruitment rate. We excluded women who had participated in a nonclinical, noninterventional research study, such as interviews, focus groups, or other market research methodology on the topic of PFDs, or clinical trial participation in the prior 6 months. The focus groups were conducted at qualitative research facilities in the vicinity of each of the seven clinic sites. Specifically, interested, eligible women contacted the designated qualitative research facility in the local community for additional screening information (e.g., age, employment, education, ethnicity) and focus-group arrangements. The local qualitative research facility offered the fourth eligible participant (and each subsequent participant thereafter if the fourth declined) an opportunity to participate in the Web-based focus groups to minimize selection bias in Web-based participant groups.
To ensure consistency across groups, the investigators developed semistructured discussion guides for studyexperienced and study-naïve participants. Three experienced female moderators co-led or observed the first two focus groups to identify any areas of the discussion guide that needed to be adapted or revised for the remaining groups. After the initial two groups, a training session was held with all moderators for the remaining groups to review the guide and ensure that all groups were conducted using a consistent approach. Each remaining focus group was conducted by two experienced female moderators, providing additional assurance that all content in the discussion guide would be addressed in each group. Informed consent was obtained from each participant at the beginning of each group. Participants provided written responses to the Pelvic Floor Distress Inventory-20 (PFDI-20), range 0-300 [9] and questions about previous PFD treatments. The groups then proceeded with the content as outlined in the discussion guide regarding their thoughts and experiences with RCTs in general and PFD clinical trials, including RCTs specifically. Analysis of results was conducted by detailed evaluation and review of the transcripts, as well as focus-group field notes.
Results
One hundred and five women, average age 58.6 years, participated in the focus groups: 93 in the in-person groups and 12 in the Web-based groups. Fifty-eight participants were studyexperienced; the remaining 47 were study-naïve. Two studyexperienced participants were incorrectly assigned to and participated in study-naïve focus-group sessions. Studygroup demographics are presented in Table 1 . Demographic and PFD characteristics were similar for the studyexperienced and study-naïve participants. More study-naïve participants had received their PFD diagnosis within the last year than study-experienced participants (38 % vs. 14 %, respectively). The overall mean ± standard deviation (SD) (range) PFDI-20 score was 80.3+56.3, (0-235). Study-naïve participants had a slightly higher mean score, reflecting greater symptoms than study-experienced participants [97.7±57.3,(0-235) vs 66.7±52.0 (0-205), P<0.01].
Treatment types most commonly reported by study participants are noted in Table 2 and reflect a wide range of treatments received or suggested to these participants. The impressions of the study-naïve participants regarding PFD clinical trial participation are listed in Table 3 and generally represent the potential benefits and risks that are discussed with participants of most types of research trials, regardless of medical condition studied.
Themes relating to participant recruitment and retention within PFD RCTs were generally similar across the focus groups and are described below.
Initial decision to participate in study Whereas most participants reported being recruited by their physicians, some first heard about a clinical trial through newspaper or radio advertisements (7), at work (5), from a friend (1), in a local city magazine (1), or from a women's health research registry newsletter (1). All five women who heard about a study at work were employed at the university or hospital conducting the research: two heard about a study from coworkers and three saw a posting in an internal newsletter, on a bulletin board, or in the restroom. Of all of these approaches, physicians were most often cited as the best source of information about a clinical trial:
& "I thought it was an excellent approach because I felt like the doctor and her staff notified me as a candidate… I usually do trust my medical people." & "I had the opportunity to ask questions of someone I trusted before doing the study."
& "I thought it was a great way to hear about it… hearing it from a physician that I trust made me want to pursue it because I trusted her."
Whereas some participants expressed concerns about recruitment from sources other than a physician, positive points of other methods of recruitment were also reported, including being able to learn more about the clinical trial at a time convenient for the patient, the confidentiality of being the one to initiate the contact about a trial, and the ability to reach participants that may have not yet seen a physician for their PFD. Examples of these statements include the following:
& "I think it was good for the advertisement to do it. It's private and confidential… it gave me the ability to call them on my time and ask questions." & "I could call after work and talk to somebody… without feeling that I was being pressured into doing something one way or another."
No participant reported finding out about their PFD study via the Web. However, several participants used the Internet to find out more information about the details of the study, including information about the physician. Likewise, participants felt information about the study on a website was a positive factor. Institutional reputation was important to some participants, who said that recruitment materials referencing a university or teaching hospital increased the perception of credibility. Most participants reported being interested in PFD clinical trial participation when first approached about a study. Participants varied in their reports about the extent to which spouses or other family members shared in the decision for them to participate. Women reported taking into consideration various benefits to their participation, with an improvement in their condition and the ability to help others being themes that were consistently reported as important. Other reported benefits were receiving the most advanced care by experts, free medical care, monetary incentives, being included in a group of women with similar problems, and learning more about their condition.
Concerns or questions that participants recalled as they made their decisions to participate included the potential for side effects, not getting the optimal treatment or receiving placebo due to randomization, discomfort of treatment, the required time commitment, how soon before treatment benefits could be expected, and being treated by an unknown physician (for those not recruited by their own physicians). Study-naïve participants reported various questions and concerns that they would like to have addressed prior to deciding to participate in a PFD clinical study, including an RCT. Many of these issues focused on whether the trial would include medication, whether there would be placebo, and about study logistics and overall time commitment Could be treated as "a number"
They are important, useful, necessary Knowing someone else has similar problems required for participation (including trial duration, frequency and duration of visits, and the distance required to travel). Additional questions and concerns included treatment shortand long-term side effects, compensation amount and type (s), provider credibility, and whether researchers would care about the individual patient. Study-naïve participants often stated that incentives would be a deciding factor, but not the primary motivation, for participation. In some groups, compensation was not even spontaneously reported as a benefit participation. However, when probed or when discussing the questions and concerns related to a clinical trial, several participants in each group typically stated that compensation was an important consideration. An amount that would factor in time and gasoline costs was often cited as the key components of compensation.
Study-experienced participants' thoughts on research participation
Study-experienced participants were highly positive about their PFD study experiences. In particular, participants saw improvements in their condition, and the relationships formed with the study staff as key benefits. In addition, they cited the quality of care they received-for example: little to no wait for appointments; procedures were quick and easy; seeing the same physician for each visit; receipt of followup care; seen by a physician if they had an issue (versus being a "regular" patient, where it may be more difficult to be seen)Further positive aspects were the education received about PFD; emotional benefits of helping others and contributing to research; feeling a part of a large group of women who shared the same condition; monetary and other incentives, such as free parking. Some participants reported finding nothing to dislike about their trial experience. Negative study experiences cited by participants were often considered as minor disappointments or inconveniences but not "deal breakers." Some negative experiences cited were aspects of the study design or procedures. Concerns raised included procedures to maintain study blinding, such as not knowing what treatment was being received; being committed for study duration, even if the treatment did not work; completing the study diary; and measuring fluid input and output. Participants often cited concerns about the frequency and repetitive nature of the study questions.
& "I just feel like it's kind of repetitive and you should just say this or this." & "You don't have to keep saying 'on a scale from 1 to 5 blah, blah, blah' and again 'on a scale from 1 to 5.' " Some participants also disliked the mode of survey administration (e.g., phone, in-person, pen and paper), but participants' experiences (mode used in her particular study) and mode preferred for use varied. Participants also expressed concerns about treatment-related issues, such as pain, discomfort, or complications. Statements included the following:
& "The catheter was awful." & "The bladder test gets uncomfortable." & "I have mixed feelings about (study drug)…someone told me that it stays in your system forever, I wasn't crazy about that."
Some participants reported that logistical issues were negative aspects to their participation, including finding appointment times that worked with their schedule, having to wait for appointments, and driving distance. A few participants cited a specific negative interaction with a study staff member, one of which caused the participant to considering withdrawing from the study. In addition, some participants discussed that the negative aspects of their participation were not anticipated by them prior to the study.
& "I thought I was going back to the same doctor for an internal and it wasn't." & "I didn't have a complete picture of what the study was about....I think they should have explained better or used more lidocaine or whatever it was that they had."
Time involvement in trial participation
Many study-experienced participants viewed annual followup visits, even for up to 10 years, as a positive aspect of clinical trial participation. A few participants mentioned hesitancy around an extended follow-up period, primarily around concerns of not remembering her original experience after such a long period of time had passed.
Improvement in PFD
Themes around the importance of improvement in the participant's PFD, as well as the benefit of helping others, were commonly cited in both groups.
& "I think for future patients that they have a chance if they find something that would help treat them." & "I have two daughters. If they were to develop this condition and this medicine was tested and it worked, then they might get more help and they won't have to live through all these years like I have."
Web-based focus-group approach
The demographics of the women who participated in the two Web-based groups are displayed in Table 4 . These participants were slightly younger on average than inperson participants.
Positive aspects of the Web-based groups were that participants stayed more "on topic," with less peripheral participant interaction; the format reduced the likelihood of one or two participants dominating the group discussion; the format allowed participants from multiple geographic locations to participate in one group. Drawbacks included: decreased interaction among participants, thus reducing some synergistic benefits of focus-group methodology; participants seemed more likely to provide "yes" or "no" responses or simply indicate agreement with others, where they may have been more likely to expand upon their thoughts if speaking rather than typing; individuals type and respond to questions at various speeds, and it was thus a challenge to set a pace that kept fast responders interested but slow enough for everyone to respond; because there was no way to know when a participant was working on a response, there were instances when participants were cut off as the group moved to the next question. Overall, for the purposes of content of these focus groups, the Web-based methodology worked well for the two groups conducted and provided similar results to the in-person groups.
Discussion
Among women with PFD, our study identified central themes guiding successful recruitment to and retention in PFD-related clinical studies, including RCTs. We also show that Internet-based collection of qualitative data is feasible and provides similar information as in-person focus groups. Both study-experienced and study-naïve women believed that their physicians were the best source of information about a clinical trial. However, other sources of trial information are necessary, and study-naïve women specifically recommend that detailed information about the study investigators and the trial, including information on study medications, inclusion of a placebo, study logistics, and overall time commitment, be available for review, as this would make them feel more comfortable calling the clinic to learn about participation. Recruitment materials that reference a university or teaching hospital lent increased credibility to studies. Further, the study-experienced patients suggested providing an additional information session prior to the first study visit to ensure that all study procedures and expectations were understood by the participants. Providing this additional visit may address some concerns reported by study-experienced patients regarding not being aware of certain aspects of the clinical trial in which they had participated.
Based on the reports provided by study-naïve participants, one would anticipate that medication trials, particularly those that include a placebo arm, will require greater recruitment efforts than those that are focused on other types of PFD treatments. In addition, the time commitment required in terms of study visit duration and frequency and trial duration should be considered at the study design and planning phases, with an emphasis on ensuring that the process is as timely and convenient for potential participants as possible.
Both study-naïve and study-experienced patients have an expectation that through research participation, they will see improvements in their health condition, but these patients also appreciate the ability to potentially help other women through study participation. The perception of research participants was that they often received (or would receive) a higher level of care than patients not involved in a study, including more direct access to the research team and to the same physician, decreased waiting times, and a more thorough education about their disorder. An unexpected benefit of participation reported by the study-experienced women (and not generally cited by the study-naïve women) was the value of a quality relationship established with the research staff. This benefit seems likely to be an important factor in retention efforts, particularly for women who do not experience improvement in their condition during the study. This relationship benefit should be communicated to study-naïve women considering participation, as it may assist with recruitment efforts. One possible method of communicating this and other benefits (as well as drawbacks) is to provide a forum in which women previously or currently participating in clinical studies could share their experiences with those considering participation. Such groups would allow studynaïve women to ask questions and learn more about participation and to feel connected to a larger group of women who share the same condition. Less important, but not unimportant, is the issue of financial compensation. Financial compensation does not appear to be a primary motivating factor for enrollment in PFD clinical studies; however, it was cited as an important consideration nonetheless. Study-experienced patients suggested that compensation strategies should take into consideration the overall time commitment (including the time and expense of traveling).
Collecting high-quality qualitative data is an integral part of patient-centered effectiveness research, and focus groups serve as an important tool in collecting these data. We found that in a PFD population, there were benefits and drawbacks to the Web-based modality: these groups stayed more "on topic," provided a greater level of anonymity, and prevented discussion domination by a few participants; however, they decreased participant interaction, a component thought to be critical for traditional focus groups. Nonetheless, we found conducting Web-based focus groups was feasible and yielded similar themes to those reported by in-person participants. This study's strengths include participation by a diverse group of women-both research-experienced and -naïve-with a spectrum of PFD. A wide age range was also represented with geographic and ethnic diversity and a broad range of levels of education. A limitation of this study was responder bias; our results may not be fully generalizable to the PFD patient population if participants view research more favorably. Concerns and deterrents to study participation were gleaned from both study-experienced and -naïve patients, but interviews with these participants cannot identify all substantial barriers to participation in clinical studies. Whereas these results should be regarded with some caution, common themes emerged from both groups of participants, and potential strategies for improved recruitment and retention were reported. Overall, experiences reported by women previously or currently participating in PFD clinical studies including RCTs, speak to the successful conduct of such studies. The information from this report will be useful in designing future PFDN studies, as this input from focus-group participants will guide study design, compensation, and follow-up strategies.
